Baxter and ScinoPharm Announce Exclusive Strategic Partnership for Generic Oncology Injectables

  Baxter and ScinoPharm Announce Exclusive Strategic Partnership for Generic
  Oncology Injectables

  * Arrangement includes five generic injectables used in cancer treatment,
    with option to add up to 15 more molecules
  * Collaboration combines ScinoPharm’s world-class API expertise with
    Baxter’s differentiated capabilities in difficult-to-manufacture oncology
    drugs and extensive global presence in hospital channel
  * Partnership augments Baxter’s growing generic injectables business with
    high-quality essential medicines that will benefit patients worldwide

Business Wire

DEERFIELD, Ill. & TAINAN, Taiwan -- February 28, 2017

Baxter International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789)
today announced a strategic partnership to develop, manufacture and
commercialize five injectable drugs used in a range of cancer treatments,
including lung cancer, multiple myeloma and breast cancer, as well as
medication to treat nausea and vomiting, common side effects of chemotherapy.
The arrangement also provides Baxter the option to partner with ScinoPharm—one
of the world’s leading active pharmaceutical ingredient (API) manufacturers—on
as many as 15 additional injectable molecules.

Under the terms of the partnership, Baxter and ScinoPharm will collaborate on
product development and manufacturing. Baxter will hold commercialization
rights, with products included in the arrangement expected to launch beginning
in 2020.

“Combining Baxter’s differentiated manufacturing expertise and global
commercialization capabilities with ScinoPharm’s recognized API experience
enables Baxter to increase patient access to difficult-to-manufacture,
high-quality oncolytic medicines,” said Robert Felicelli, president,
Pharmaceuticals, Baxter. “The ScinoPharm collaboration will further expand
Baxter’s presence in generic injectables, which will continue to be enhanced
through our recently executed agreement to acquire Claris Injectables
Limited.”

Current branded sales of the initial five products included in this
partnership total more than $4 billion annually. These products will join
Baxter’s existing portfolio of generic injectable medications, which includes
difficult-to-manufacture oncology drugs and a broad portfolio of
standard-dose, ready-to-use premixed injectable products such as
anti-infectives, analgesics and critical care medicines.

ScinoPharm has a 17-year history of manufacturing APIs for the global
pharmaceutical industry with a high level of quality and safety. Under the
arrangement, ScinoPharm will provide APIs for the initial five generic
injectables, and Baxter and ScinoPharm will share manufacturing
responsibilities, with the majority of the molecules to be manufactured at
Baxter’s state-of-the-art facility in Halle, Germany, one of the most advanced
facilities in the world for manufacturing oncology drugs.

“We are very excited to partner with Baxter. We bring complementary strengths
to this arrangement that will ultimately lead to more injectable oncology
products on the market,” said ScinoPharm CEO Dr. Yung Fa Chen. “This strategic
partnership will boost our expansion in the formulation business, increase
market coverage of our products and eventually fuel our further operating
performance.”

About ScinoPharm

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service
provider to the global pharmaceutical industry. With research and
manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide
portfolio of services ranging from custom synthesis for early phase
pharmaceutical activities for brand companies as well as APIs for the generic
industry. The Company also is aggressively pursuing a vertically integrated,
one-stop-shopping service for drug product customers by expanding into the
field of sterile oncological injectable formulations.

About Baxter

Baxter International Inc. provides a broad portfolio of essential renal and
hospital products, including home, acute and in-center dialysis; sterile IV
solutions; infusion systems and devices; parenteral nutrition; biosurgery
products and anesthetics; and pharmacy automation, software and services. The
company’s global footprint and the critical nature of its products and
services play a key role in expanding access to healthcare in emerging and
developed countries. Baxter’s employees worldwide are building upon the
company’s rich heritage of medical breakthroughs to advance the next
generation of healthcare innovations that enable patient care.

Forward Looking Statement for Baxter

This release includes forward-looking statements concerning the entry by
Baxter and ScinoPharm into a joint development agreement, including
expectations regarding the number of molecules to be developed under the
partnership agreement and the value of the co-developed molecules. The
statements are based on assumptions about many important factors, including
the following, which could cause actual results to differ materially from
those in the forward-looking statements: the ability of Baxter and ScinoPharm
to develop, manufacture and commercialize new molecules in accordance with the
terms of the agreement; continued strength in the financial position,
including cash flows, of Baxter and ScinoPharm; actions of regulatory bodies
and other governmental authorities; changes in laws and regulations; and other
risks identified in Baxter’s most recent filing on Form 10-K and other SEC
filings, all of which are available on its website. Baxter does not undertake
to update its forward-looking statements.

Forward Looking Statement for ScinoPharm

This press release contains forward-looking statements. These forward-looking
statements are based on current information and expectations, and are subject
to risks and uncertainties, including market conditions and other factors
outside of ScinoPharm’s control. Readers are cautioned not to place undue
reliance on the forward-looking statements contained herein, which speak only
as of the date hereof. ScinoPharm undertakes no obligation to publicly update
any forward-looking statement contained in this release, whether as a result
of new information, future developments or otherwise, except as may be
required by law.

View source version on businesswire.com:
http://www.businesswire.com/news/home/20170228006007/en/

Contact:

Baxter International Inc.
Media Contacts:
Bill Rader, (224) 948-5353
Eric Tatro, (224) 948-5353
media@baxter.com
or
Investor Contact:
Clare Trachtman, (224) 948-3085
Press spacebar to pause and continue. Press esc to stop.